CD4 and glioma: In addition to the activation of antitumor effector cells, TIO3 also reduced the expression of PD1 on CD4+ T cells, CD8+ T cells and NK cells and inhibited PD-L1 expression in glioma tissues and tumor-infiltrating neutrophils.